A double-blind placebo controlled trial of fluoxetine in fibromyalgia

Scandinavian Journal of Rheumatology

Volumn 23, Issue 5, 1994, Pages 255-259

  Wolfe, F ^a   Cathey, M A ^a   Hawley, D J ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b WICHITA STATE UNIVERSITY   (United States)

Author keywords

Controlled trial; Depression; Fibromyalgia; Fluoxetine; Pain

Indexed keywords

FLUOXETINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FIBROMYALGIA; HUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANXIETY; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; FLUOXETINE; HUMANS; MIDDLE AGED; PAIN MEASUREMENT; PSYCHIATRIC STATUS RATING SCALES;

EID: 0028113008     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009749409103725     Document Type: Article

References (37)

1. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia
2. Short term effects of ibuprofen in primary fibromyalgia syndrome: A double blind, placebo controlled trial
3. A comparison of cyclobenzaprine and placebo in the management of fibrositis: A double-blind controlled study
4. A controlled trial of amitriptyline (AM), cyclobenzaprine (CY) and placebo (P) in fibromyalgia
5. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study
6. Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome
7. Clinical trials in fibrositis: a critical review and future directions
8. N of 1 randomized trials for investigating new drugs
9. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials
10. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia
11. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia
12. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline
13. Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects
14. Plasma tryptophan and musculoskeletal pain in nonarticular rheumatism (“fibrositis syndrome”)
15. Rheumatic pain modulation syndrome: the interrelationships between sleep, central nervous system serotonin, and pain
16. Proposed pathogenesis of fibrositis
17. Sleep and fibrositis syndrome
18. Biochemical Clues to a Fibromyalgia-Depression Link-Imipramine Binding in Patients with Fibromyalgia or Depression and in Healthy Controls
19. Is there a metabolic basis for the fibrositis syndrome?
20. Serum amino acids in fibrositis/fibromyalgia syndrome
21. Neurohormonal aspects of the fibromyalgia syndrome
22. Cerebrospinal fluid monoamines in primary fibromyalgia
23. Cerebrospinal Fluid Biogenic Amine Metabolites in Fibromyalgia/Fibrositis Syndrome and Rheumatoid Arthritis
24. Platelet H-3-Imipramine Uptake Receptor Density and Serum Serotonin Levels in Patients with Fibromyalgia/Fibrositis Syndrome
25. Plasma Tryptophan and Other Amino Acids in Primary Fibromyalgia-A Controlled Study
26. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study
27. Fixed-dose fluoxetine therapy for depression
28. Treatment of fibrositis with fluoxetine hydrochloride Prozac
29. Fluoxetine and fibromyalgia letter
30. Evaluation of the Effectiveness of a Serotonin-Agonist (Fluoxetin Hydrochloride)-An Open Study in Patients with Fibromyalgia
31. Statistical considerations for performing multiple tests in a single experiment. 6. Testing accumulating data repeatedly over time
32. Fibrositis: symptom frequency and criteria for diagnosis. An evaluation of 291 rheumatic disease patients and 58 normal individuals
33. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: Report of the Multicenter Criteria Committee
34. New approaches to outcome assessment: The AIMS questionnaire for arthritis
35. Depression is not more common in rheumatoid arthritis: a 10 year longitudinal study of 6,608 rheumatic disease patients
36. SAS Institute